Results 141 to 150 of about 22,545,234 (252)

Microfluidic Molecular Diagnostic Chips: Functional Modules, Integration Strategies, and Emerging Applications

open access: yesSmall Methods, EarlyView.
This comprehensive review delivers an engineering‐centric analysis of microfluidic molecular diagnostic chips, breaking them down into foundational modules from fluid manipulation to bio‐sensing. Beyond chip design, it evaluates sample‐to‐answer integration strategies and commercial readiness levels.
Donghoon Koo   +7 more
wiley   +1 more source

CD200 Expression in Folliculotropic Mycosis Fungoides Emerging During Dupilumab Treatment

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Folliculotropic mycosis fungoides (FMF) or mycosis fungoides with folliculotropism (MF‐F) is increasingly recognized in patients initially diagnosed with atopic dermatitis (AD) who subsequently worsen during dupilumab therapy. We report a case of FMF that became clinically apparent after dupilumab treatment.
Mai Tamaki   +9 more
wiley   +1 more source

T Cell Microenvironmental Impacts and Therapeutic Opportunities: Application to Human Testicular Germ Cell Tumors

open access: yesAndrology, EarlyView.
ABSTRACT Testicular germ cell tumors (TGCT) are the leading malignancy in adolescent and young adult males, yet the immunological and cellular mechanisms governing their tumor microenvironment (TME) remain poorly understood. Here, we present a comprehensive review of TGCT pathobiology with a focus on the immune landscape, particularly the role of tumor‐
R Islam   +7 more
wiley   +1 more source

Interferon Alfa in the treatment of B-cell chronic lymphocytic leukemia [PDF]

open access: yes, 1994
Knauf, W. U.   +10 more
core   +1 more source

B-cell chronic lymphocytic leukemia

open access: yes, 2013
Francesco Bertoni   +6 more
openaire   +1 more source

Radiation therapy for persistent or progressive mediastinal lymphoma after chemotherapy in FeLV‐positive cats: a retrospective case series of four cats

open access: yesAustralian Veterinary Journal, EarlyView.
Background Mediastinal lymphoma in feline leukaemia virus (FeLV)‐positive cats is associated with a poor prognosis, and therapeutic options may be limited when adequate disease control is not achieved with chemotherapy. The efficacy of radiation therapy in this setting has not been established.
A Uno, T Hasegawa, T Mori
wiley   +1 more source

Predicted microbiome‐associated metabolic pathways are linked to immune checkpoint modulation in chronic lymphocytic leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
Summary Microbial metabolites are key regulators of host immunity, yet their functional impact in chronic lymphocytic leukaemia (CLL) remains unclear. Following up on our earlier observations of microbiome dysbiosis in CLL, we performed predictive metabolic profiling based on 16S ribosomal RNA (rRNA) sequencing of oral and stool samples collected from ...
Monika Szelest   +15 more
wiley   +1 more source

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

open access: yesBritish Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa   +25 more
wiley   +1 more source

The expanding role of bendamustine in chronic lymphocytic leukemia

open access: yes, 2015
Kruti Sheth Nair, Chaitra Ujjani Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA Abstract: As the most prevalent form of adult leukemia, chronic lymphocytic leukemia (CLL) affects thousands of patients ...
Nair KS, Ujjani C
core  

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

open access: yesBritish Journal of Haematology, EarlyView.
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz   +45 more
wiley   +1 more source

Home - About - Disclaimer - Privacy